Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $11.31 million. The enterprise value is $11.03 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 6.25 million shares outstanding. The number of shares has increased by 84.23% in one year.
| Current Share Class | 6.25M |
| Shares Outstanding | 6.25M |
| Shares Change (YoY) | +84.23% |
| Shares Change (QoQ) | +30.13% |
| Owned by Insiders (%) | 16.27% |
| Owned by Institutions (%) | 1.46% |
| Float | 4.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.75 |
| Forward PS | n/a |
| PB Ratio | 0.49 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.05 |
| Quick Ratio | 0.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -601.44 |
Financial Efficiency
Return on equity (ROE) is -118.31% and return on invested capital (ROIC) is -68.38%.
| Return on Equity (ROE) | -118.31% |
| Return on Assets (ROA) | -62.72% |
| Return on Invested Capital (ROIC) | -68.38% |
| Return on Capital Employed (ROCE) | -59.09% |
| Revenue Per Employee | $205,291 |
| Profits Per Employee | -$3.19M |
| Employee Count | 3 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.01% in the last 52 weeks. The beta is 2.42, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.42 |
| 52-Week Price Change | -55.01% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 3.46 |
| Relative Strength Index (RSI) | 39.29 |
| Average Volume (20 Days) | 404,786 |
Short Selling Information
The latest short interest is 244,846, so 3.92% of the outstanding shares have been sold short.
| Short Interest | 244,846 |
| Short Previous Month | 72,618 |
| Short % of Shares Out | 3.92% |
| Short % of Float | 5.59% |
| Short Ratio (days to cover) | 1.02 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $615,873 and -$9.58 million in losses. Loss per share was -$4.84.
| Revenue | 615,873 |
| Gross Profit | 379,964 |
| Operating Income | -8.24M |
| Pretax Income | -9.02M |
| Net Income | -9.58M |
| EBITDA | -7.51M |
| EBIT | -8.24M |
| Loss Per Share | -$4.84 |
Full Income StatementBalance Sheet
The company has $58,653 in cash and $214,962 in debt, giving a net cash position of -$156,309 or -$0.03 per share.
| Cash & Cash Equivalents | 58,653 |
| Total Debt | 214,962 |
| Net Cash | -156,309 |
| Net Cash Per Share | -$0.03 |
| Equity (Book Value) | 13.95M |
| Book Value Per Share | 4.30 |
| Working Capital | -1.35M |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.86M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.86M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
| Gross Margin | 61.70% |
| Operating Margin | -1,337.90% |
| Pretax Margin | -1,413.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |